Pinc PeptideThe girly peptide research blog

Sexual health · Evidence tier A · #11 in test requests

PT-141 (bremelanotide)

bremelanotide · Vyleesi (US brand name) · PT 141 · bremelanotide acetate (salt form) · BMT (abbreviation used in trials)

PT-141 is bremelanotide, approved in the US as Vyleesi for low sexual desire in women before menopause110. It helps a little, nausea is common, and ‘PT-141’ vials sold online are not approved123.

Last reviewed · First published · 54 sources · 30 min read · By the Pinc Peptide editors

Illustration: a glass vial with a pink label reading PT-141
Illustration, not a real product: an empty glass vial (photo: Missouri Historical Society, public domain) with our label. See every vial.

Quick answers

What is it?
The code name for bremelanotide, a lab-made peptide110. As Vyleesi, it is an FDA-approved injection for low sexual desire in women before menopause14. Unapproved ‘PT-141’ vials are also sold online337.
Does it work?
A little, for its approved use. In two large trials, it raised desire slightly more than placebo, but not how often women had satisfying sex2. Work in men was dropped after FDA concerns in 2007; we found no results from a study announced in 202478444849.
Is it safe?
Side effects are common. In large trials, 4 in 10 women had nausea1. Each dose raises blood pressure, and frequent use often darkens patches of skin1510. The label’s data on daily use cover only up to 16 days1.
Is it legal?
Approved in the US only as Vyleesi, for low sexual desire in women before menopause14. FDA treats ‘PT-141’ research vials as unapproved drugs3. Whether US pharmacies may make it is unclear429. Not on sport’s banned list3435.
What is in the vials?
Finnrick, a testing service, failed 53 of 151 samples from March 2025 to September 202643. A vial from a Brooklyn corner shop, tested for WIRED, held no PT-1419. No approved application covers research vials, so FDA has not reviewed their quality3.

What it is

PT-141 is the development code for bremelanotide, a synthetic, ring-shaped peptide made of seven amino acids110. It is built on alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone, and switches on melanocortin receptors2. This receptor family is involved in sexual function, feeding, immune function and skin pigment110. Bremelanotide acts most strongly on MC1R, found on pigment cells, where activation darkens skin, and on MC4R, found on nerve cells in many areas of the brain1. Animal work points to an effect on brain circuits for sexual motivation11, and in a small human study it raised reported desire without changing measured genital blood flow12. The label states that how it improves low desire in women is unknown1. It is nearly identical to melanotan II: the ring is the same, but PT-141 ends in an acid group where melanotan II ends in an amide1314.

Palatin Technologies, then based in Cranbury, New Jersey, developed PT-141 as an analog of melanotan II815. Early studies in men, published in 2004, tested nasal and injected doses for erectile dysfunction616. In 2007 FDA questioned the efficacy and clinical benefit of that program and cited blood pressure increases, and partner King Pharmaceuticals ended its deal effective December 200778. Development then focused on women and moved from the nasal spray to injection, because nasal absorption varied10. AMAG Pharmaceuticals filed for approval on 23 March 2018, FDA approved Vyleesi on 21 June 2019, and Palatin sold Vyleesi to Cosette Pharmaceuticals in December 202341017.

Benefits: what the research shows

The best evidence comes from two identical Phase 3 randomized controlled trials (RCTs) of as-needed 1.75 mg injections in 1,267 premenopausal women with HSDD, called RECONNECT2. From each woman’s starting score to her last visit (week 24 for those who finished), desire scores rose 0.30 and 0.42 points more than with placebo on a 1.2–6 scale, and distress about low desire fell 0.37 and 0.29 points more on a 0–4 scale12. Women who stopped early were counted with their last score, and more stopped early on the drug than on placebo (40% vs 13% and 39% vs 25%)1. The number of satisfying sexual events, the key secondary outcome, did not differ from placebo2. Among women whose answer was recorded, about 58% on the drug and 36% on placebo rated it as beneficial, so the placebo response was large; the authors report, without giving figures, that the drug still came out ahead when every woman who stopped early was counted as not helped2. Scores stayed improved in a 52-week open-label extension, but it had no control group and only 272 of 684 women finished it18. In an earlier 12-week Phase 2b trial, satisfying events rose by 0.7 a month with the pooled 1.25 and 1.75 mg doses versus 0.2 with placebo19. Across the whole program, about 3,500 people took part in 43 completed studies20. Evidence in men is thin. Small early laboratory studies found dose-related erections after injected doses above 1 mg or nasal doses above 7 mg, including in men with a poor response to Viagra616. In 2007 Palatin and King put off Phase 3 trials in men after FDA questioned the efficacy results and clinical benefit and called blood pressure increases its greatest safety concern, and Palatin later discontinued that work78. A 2008 trial in 342 men who did not respond to sildenafil (Viagra) is under a 2023 journal expression of concern, so we do not report its results4647. In June 2024 Palatin announced an open-label study of about 50 men combining bremelanotide with a PDE5 inhibitor (a Viagra-type drug), and in October 2024 it planned a later Phase 2/3 trial; as of 8 October 2026 we found no results and no ClinicalTrials.gov record44454849. In two short Phase 1 trials in women with obesity, injections three times a day for 15 days led to 1.3 kg more weight loss than placebo by day 16, with skin darkening in 63%; in the second trial, with 4-day treatment periods, weight fell 1.7 kg with two doses a day versus 0.9 kg with placebo5. In a Phase 2 obesity trial that Palatin reported in a press release, 96 people were randomized after 4 weeks on tirzepatide; over the 8 weeks, weight fell 4.4% with daily 1.25 mg bremelanotide plus tirzepatide and 1.6% in the group switched to placebo, and 40% versus 27% lost 5% of their weight with the combination versus tirzepatide alone5053. In an open-label study, also reported only in a press release, 16 people with type 2 diabetic kidney disease were enrolled to take bremelanotide twice a day for six months (8 finished), and Palatin reported skin darkening in 71% of patients without giving the number5152. In female rats, it increased behaviors that invite mating without changing reflexive sexual responses11.

Key human studies

StudyDesignPeopleDose and routeResult
Kingsberg et al., Obstet Gynecol 2019 (RECONNECT studies 301 and 302)2PubMed · DOI · NCT02333071 · NCT02338960 Two identical Phase 3, randomized, double-blind, placebo-controlled trials, 24 weeks, after a 4-week single-blind placebo run-in; premenopausal women with acquired, generalized HSDD 1,267 1.75 mg subcutaneous autoinjector as needed, about 45 minutes before sexual activity; at most 1 dose per 24 hours and 12 doses per 4 weeks Change from baseline to end of study (each woman’s last double-blind visit; last observation carried forward; modified intent-to-treat): Desire score (FSFI desire domain) +0.30 and +0.42 vs placebo; distress (FSDS-DAO item 13) -0.37 and -0.29 vs placebo (P<.001 to P=.005). No difference in satisfying sexual events. Nausea 40.0% vs 1.3%. More stopped early on the drug (40% and 39%) than on placebo (13% and 25%)1.
Simon et al., Obstet Gynecol 2019 (RECONNECT open-label extension)18PubMed · DOI · NCT02333071 · NCT02338960 52-week open-label extension of the two Phase 3 trials; uncontrolled, descriptive statistics only 684 1.75 mg subcutaneous as needed 272 completed. Drug-related side effects: nausea 40.4%, flushing 20.6%, headache 12.0%. Desire score change from core-study baseline +1.25 to +1.30 in women on drug throughout; no new safety signals.
Clayton et al., Womens Health (Lond) 2016 (Phase 2b)19PubMed · DOI · NCT01382719 Phase 2b randomized, placebo-controlled dose-finding trial, 12 weeks; premenopausal women with female sexual dysfunction (HSDD and/or arousal disorder); 397 randomized, 327 in efficacy analysis 327 0.75, 1.25 or 1.75 mg subcutaneous, self-administered as desired Pooled 1.25/1.75 mg vs placebo: +0.7 vs +0.2 satisfying sexual events a month (p=0.018); FSFI total score +3.6 vs +1.9 (p=0.0017). Blood pressure monitoring in the same trial found systolic rises of about 3 mmHg vs placebo in the 4 hours after 1.75 mg doses, with heart rate 4.6 to 4.7 beats per minute lower21.
Rosen et al., Int J Impot Res 20046PubMed · DOI Early randomized, placebo-controlled studies in healthy men (dose escalation) and in men with erectile dysfunction and an inadequate response to Viagra (crossover); erections measured by RigiScan – Subcutaneous doses of 0.3 to 10 mg (healthy men); 4 or 6 mg in a crossover (patients) Significant erectile response above 1.0 mg in healthy men, and at both 4 and 6 mg in patients viewing sexual stimulation. Short-term use was reported as safe and well tolerated.
Diamond et al., Int J Impot Res 200416PubMed · DOI Double-blind, placebo-controlled studies in healthy men and in Viagra-responsive men with mild-to-moderate erectile dysfunction; erections measured by RigiScan – Intranasal doses; erectile effects above 7 mg Erections began about 30 minutes after doses above 7 mg. Peak blood levels at 0.5 hours; half-life 1.85 to 2.09 hours. Flushing and nausea were the most common side effects.
Diamond et al., J Sex Med 200612PubMed · DOI Randomized, double-blind, placebo-controlled crossover; premenopausal women with female sexual arousal disorder 18 Single 20 mg intranasal dose More women reported moderate or high desire after the drug than after placebo (P=0.0114). Measured vaginal blood flow during erotic video did not change significantly.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

Approved label: 1.75 mg injected under the skin as needed, at least 45 minutes before expected sexual activity; no more than one dose in 24 hours; more than 8 doses a month is not recommended; stop after 8 weeks without improvement1. Phase 3 allowed up to 12 doses per 4 weeks2, but women used it two to three times a month on average10. Phase 2b tested 0.75, 1.25 and 1.75 mg under the skin as desired19. Early studies in men used injected doses of 0.3 to 10 mg, with erectile effects above 1.0 mg6, and nasal doses, with erectile effects above 7 mg16; a study in women used one 20 mg nasal dose12. Phase 1 weight studies in women with obesity gave three injections a day for 15 days (2.5 mg, then 2.0 mg twice, after a lower first day), or 2.5 mg once a day or 2.5 mg plus 2.0 mg a day in 4-day periods5. A Phase 2 obesity trial gave 1.25 mg once a day for 4 weeks, with or without tirzepatide5053, and a study in type 2 diabetic kidney disease gave 0.5 mg twice a day for six months5152. The longest daily dosing described in the label is 16 days1.

In animal studies

Female rats: injections under the skin of 50, 100 or 200 µg/kg were given 5 minutes before mating tests; 100 and 200 µg/kg significantly increased solicitation (mating-invitation) behavior11. Reproductive toxicity: pregnant dogs received 2, 8 or 20 mg/kg under the skin on gestation days 18 to 35, with 3- to 8-fold more post-implantation loss at every dose; pregnant mice received 30, 75 or 150 mg/kg/day, with developmental delays in offspring at 30 mg/kg/day and above1.

What users report Anecdotal · not validated · not a recommendation

A dosing-protocol website (updated 20 September 2026) lists 500 µg to 1.5 mg injected under the skin once a day36.

Half-life
about 2.7 hours (range 1.9–4.0 hours)1Mean terminal half-life in humans after a single subcutaneous dose of Vyleesi; blood levels peak about 1 hour after injection
Routes
  • Subcutaneous injection: the approved Vyleesi autoinjector; Phase 2 and Phase 3 human data
  • Intranasal spray: early Phase 1 and 2 studies in men and women; dropped because absorption varied
  • Intravenous: used in some early company studies
  • Gray-market vials are sold as powder for injection; nasal products were not verified

Every dose studied for PT-141 (bremelanotide), with sources →

Quality and the gray market

What testing finds

The testing service Finnrick lists 151 PT-141 tests of products from 44 vendors, dated 16 March 2025 to 5 September 2026. Of these, 95 passed, 53 failed and 3 were incomplete, so about 36% of completed tests failed (our calculation). Finnrick’s ‘purity focus’ standard is 99.5% purity or better and a dose within 35% of the label43. In a report published 15 September 2026, WIRED bought a ‘PT-141’ vial (INDR Labs brand) at a Brooklyn bodega and had it tested through Finnrick. It did not contain the labeled active ingredient, though heavy metals and endotoxin were low9. That is one product from one seller. WIRED also reported, citing CBS News, that the lab named on that brand’s certificates of analysis denied issuing them9. Sellers advertise high purity (one lists ‘99%+ by HPLC’) and post certificates of analysis that they say come from third-party labs3738. FDA’s import alert records a seller posting a ‘98.24%’ purity chromatogram for its ‘PT-141’ on Facebook in 201926.

How it is sold

‘PT-141’ is sold online as a ‘research use only’ freeze-dried powder, for example in 10 mg vials. On 1 October 2026, two US sites listed a 10 mg vial at $43 and $49 (sale price; $59.99 list), and both said it is not for human use3738. It ranked ninth in one vendor’s popularity-sorted list on 30 September 2026; such rankings are vendor-controlled39. It also turns up in clinics and shops: a 2025 Health Canada notice reports injectable PT-141 seized from a Calgary wellness clinic32, and WIRED bought a vial at a Brooklyn bodega in 20269. FDA’s 2020 import alert entry quotes a Montreal seller’s president advising buyers on social media how to use it26. Demand is modest next to weight-loss peptides: adding up the monthly figures in Finnrick’s chart of test requests gives about 290 for PT-141 from May 2025 to May 2026, against more than 7,000 for retatrutide (our calculation)40.

Side effects and risks

  • Blood pressure and heart rate: each dose raises blood pressure (up to 6 mmHg systolic, peaking 2 to 4 hours later) and lowers heart rate by up to 5 beats per minute. The label rules out use with uncontrolled high blood pressure or known heart disease1.
  • Nausea: reported by 40% in Phase 3; 13% needed anti-nausea medicine and 8% quit because of it1.
  • Skin darkening (focal hyperpigmentation) of the face, gums or breasts: 1% at up to 8 doses a month, but 38% after 8 daily doses1, and 63% in a 15-day study with three doses a day5. In Phase 3, fading was documented in only half of cases during follow-up10.
  • Frequent use: an online dosing protocol describes daily injections36, far beyond the label’s limit of 8 doses a month and the 16 days of daily dosing it describes1.
  • Dose stacking: 3.9% of Phase 3 participants took two doses less than 12 hours apart. Closely spaced doses may add to the blood pressure effect110.
  • Interactions: it may slow stomach emptying and affect the absorption of drugs taken by mouth, and it may significantly lower blood levels of oral naltrexone, a treatment for alcohol and opioid addiction, so the label says to avoid that combination1.
  • Pregnancy: fetal harm in dogs at 16 times the human exposure or more. The label advises contraception and stopping if pregnancy is suspected1.
  • Use in men is not approved1. Palatin dropped its men’s program before any phase 3 trial, after FDA called blood pressure increases its greatest safety concern; it announced a small new study in men in 2024, and we found no results78444849.
  • Product and legal risk: research-chemical vials have no approved application, so FDA has not reviewed their quality, and FDA treats them as unapproved new drugs3. Finnrick, a testing service, failed 53 of 151 samples from March 2025 to September 2026, and a bodega vial tested for WIRED held no PT-141943.

Documented harms

  • Jun 2019The Vyleesi label, in its 2019 original and current versions, describes one case of acute hepatitis in a trial extension, in a woman who had taken 10 doses over one year. Liver enzymes rose above 40 times normal and returned to normal 4 months after stopping; a role for the drug could not be excluded, and the trials showed no other sign of liver harm141.
  • Apr 2025Health Canada warned that injectable peptides seized from a Calgary wellness clinic, including PT-141, ‘may pose serious health risks’32.
  • 30 Jul 2026FDA’s adverse event database (FAERS) held 1,004 reports naming bremelanotide: 31 classed as serious and 973 not4254. The most frequent terms were nausea (432), drug ineffective (202), headache (148) and vomiting (115). Reports are unverified and do not prove the drug caused the event42.

Questions people ask

Is PT-141 the same as Vyleesi?

Same molecule, different products. Vyleesi is an FDA-approved 1.75 mg bremelanotide autoinjector1. ‘PT-141’ vials sold online are research chemicals that FDA treats as unapproved new drugs3, and the one bodega vial tested for WIRED held none of the labeled peptide9.

Is PT-141 FDA approved?

Only as Vyleesi, approved on 21 June 2019 for premenopausal women with acquired, generalized low sexual desire (HSDD)14. It is not approved for men, postmenopausal women or performance, and ‘PT-141’ research vials are not approved for any use13.

Does PT-141 work for men?

Small early studies found dose-related erections in the lab, including in some men who did not respond well to Viagra616. After FDA questioned the benefit and cited blood pressure increases in 2007, the program in men was halted78. A 2008 trial in 342 men who did not respond to Viagra is under a journal’s expression of concern, so we do not report its results4647. In June 2024 Palatin announced a small study combining bremelanotide with a Viagra-type drug in men for whom such drugs alone do not work; we found no results as of 8 October 202644454849.

PT-141 vs melanotan II: what’s the difference?

They are close chemical cousins with the same seven amino acids and the same ring; PT-141 ends in an acid group and melanotan II in an amide1314. PT-141 was developed as a melanotan II analog15. It acts most strongly on MC1R, the skin-pigment receptor, which is why frequent use can darken skin1.

How long does PT-141 last, and what are the side effects?

Blood levels peak about 1 hour after an injection and halve about every 2.7 hours; the label says how long the effect on desire lasts is unknown1. The most common side effects are nausea, flushing, injection-site reactions, headache and vomiting1.

What is still unknown

  • Effects of daily or near-daily use for weeks to months, the pattern an online dosing protocol describes; the label describes at most 16 days of daily dosing, and the one six-month study we found (16 people, reported in a press release) gives only its skin-darkening rate.
  • What ‘PT-141’ vials that fail testing contain instead; the lab that tested WIRED’s vial checks whether the labeled compound is present (it also found low heavy metals and endotoxin), so it could not say what the vial held.
  • Whether bremelanotide improves erections or desire in men in a large trial with trustworthy results: the one large trial we found is under an expression of concern, and we found no results from the study Palatin announced in 2024.
  • Current approval status in China, South Korea, the UK and other countries was not verified.
  • Whether FDA accepts 503A compounding of bremelanotide as a component of an approved drug; we found no FDA statement on it.
  • Whether nasal-spray ‘PT-141’ products are widely sold was not verified.
  • Vendor and dosing sites call PT-141 a ‘metabolite’ of melanotan II; we found no primary source for this.
  • Whether skin darkening from repeated use fully reverses; in the Phase 3 trials, clearing was documented in only about half of cases during follow-up.

Sources

  1. 1VYLEESI (bremelanotide injection) prescribing information Cosette Pharmaceuticals via DailyMed (U.S. National Library of Medicine), 13 Nov 2025. dailymed.nlm.nih.gov
  2. 2Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstetrics & Gynecology, Nov 2019. pubmed.ncbi.nlm.nih.gov
  3. 3Warning letter to Peak Performance Peptides (MARCS-CMS 735127) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  4. 4Drugs@FDA record for NDA 210557 (Vyleesi), openFDA drugsfda endpoint U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
  5. 5Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials Diabetes, Obesity and Metabolism, Jun 2022. pmc.ncbi.nlm.nih.gov
  6. 6Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra International Journal of Impotence Research, Apr 2004. pubmed.ncbi.nlm.nih.gov
  7. 7King Pharmaceuticals and Palatin Technologies delay immediate plans for Phase 3 clinical program with bremelanotide for erectile dysfunction (Form 8-K, Exhibit 99) Palatin Technologies via SEC EDGAR, 30 Aug 2007. sec.gov
  8. 8Palatin Technologies Form 10-K for the fiscal year ended June 30, 2008 Palatin Technologies via SEC EDGAR, 29 Sep 2008. sec.gov
  9. 9Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
  10. 10NDA 210557 Multi-discipline Review and Evaluation (bremelanotide) U.S. Food and Drug Administration, CDER, Jun 2019. accessdata.fda.gov
  11. 11Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist Proceedings of the National Academy of Sciences, 6 Jul 2004. pmc.ncbi.nlm.nih.gov
  12. 12An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist Journal of Sexual Medicine, Jul 2006. pubmed.ncbi.nlm.nih.gov
  13. 13Bremelanotide (CID 9941379) PubChem, NCBI, accessed 1 Oct 2026. pubchem.ncbi.nlm.nih.gov
  14. 14Melanotan II (CID 92432) PubChem, NCBI, accessed 1 Oct 2026. pubchem.ncbi.nlm.nih.gov
  15. 15Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization Peptides, Apr 2006. pubmed.ncbi.nlm.nih.gov
  16. 16Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction International Journal of Impotence Research, Feb 2004. pubmed.ncbi.nlm.nih.gov
  17. 17Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 Million (Form 8-K, Exhibit 99.1) Palatin Technologies via SEC EDGAR, 20 Dec 2023. sec.gov
  18. 18Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder Obstetrics & Gynecology, Nov 2019. pubmed.ncbi.nlm.nih.gov
  19. 19Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial Women’s Health (London), Jun 2016. pubmed.ncbi.nlm.nih.gov
  20. 20Safety Profile of Bremelanotide Across the Clinical Development Program Journal of Women’s Health, Feb 2022. pubmed.ncbi.nlm.nih.gov
  21. 21Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide Journal of Hypertension, Apr 2017. pubmed.ncbi.nlm.nih.gov
  22. 22Warning letter to Royal Peptides LLC (MARCS-CMS 734884) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  23. 23Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  24. 24Warning letter to Peptide Partners LLC (MARCS-CMS 735063) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  25. 25Warning letter to TXP Innovations LLC dba Tex Peptides (MARCS-CMS 735067) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  26. 26Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. U.S. Food and Drug Administration, 1 Oct 2026. accessdata.fda.gov
  27. 27Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  28. 28Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
  29. 29Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
  30. 30Download medicine data: medicines table (centrally authorised and assessed human medicines) European Medicines Agency, 30 Sep 2026. ema.europa.eu
  31. 31Drug Product Database API: active ingredient search for bremelanotide (0 products on 8 October 2026) Health Canada, accessed 8 Oct 2026. health-products.canada.ca · data query
  32. 32Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks (RA-77218) Health Canada, 1 Apr 2025. recalls-rappels.canada.ca
  33. 33Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  34. 34World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  35. 35World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  36. 36PT-141 (10 mg Vial) Dosage Protocol PeptideDosages.com, 20 Sep 2026. peptidedosages.com
  37. 37PT-141 (Bremelanotide) – 10MG product page Core Peptides (vendor), accessed 8 Oct 2026. corepeptides.com (seller page, deliberately not linked)
  38. 38PT-141 (10MG) product listing Ascension Peptides (vendor), accessed 8 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  39. 39Core Peptides shop page sorted by popularity Core Peptides (vendor), accessed 30 Sep 2026. corepeptides.com (seller page, deliberately not linked)
  40. 40We’d Rather Buy the Future Than Wait For It Finnrick, 10 Jun 2026. finnrick.com
  41. 41VYLEESI prescribing information, original approval label (Revised 6/2019) U.S. Food and Drug Administration (Drugs@FDA), Jun 2019. accessdata.fda.gov
  42. 42FAERS reports naming bremelanotide, counted by reaction term (openFDA drug event endpoint) U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query
  43. 43PT-141 Safety Testing Results & Vendor Ratings Finnrick, accessed 8 Oct 2026. finnrick.com
  44. 44Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) Palatin Technologies, 20 Jun 2024. palatin.com
  45. 45Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones Palatin Technologies, 1 Oct 2024. palatin.com
  46. 46Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study The Journal of Urology, Mar 2008. pubmed.ncbi.nlm.nih.gov
  47. 47Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study The Journal of Urology, 10 Jan 2023. pubmed.ncbi.nlm.nih.gov
  48. 48PubMed search: (bremelanotide OR “PT-141” OR “PT 141”) AND (erectile OR men OR male), limited to clinical trials and randomized controlled trials (6 results on 8 October 2026; the only large trial is a 2008 trial of 342 men under an expression of concern) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  49. 49ClinicalTrials.gov search for condition ‘erectile dysfunction’ and intervention ‘bremelanotide’ (0 studies on 8 October 2026; 0 with ‘PT-141’) ClinicalTrials.gov, accessed 8 Oct 2026. clinicaltrials.gov
  50. 50Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study Palatin Technologies, 31 Mar 2025. palatin.com
  51. 51Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Technologies, 19 Dec 2024. palatin.com
  52. 52A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease (NCT05709444) ClinicalTrials.gov, 17 Oct 2024. clinicaltrials.gov
  53. 53A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity (NCT06565611) ClinicalTrials.gov, 6 Mar 2025. clinicaltrials.gov
  54. 54FAERS reports naming bremelanotide, counted by seriousness (openFDA drug event endpoint) U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.